Introduction
Neisseria meningitidis is a major cause of epidemics in subSaharan Africa [1] . These were mainly caused by strains belonging to capsular group A, but there has been an increasing contribution of serogroups W and X strains with epidemic potential in the last two decades [2] [3] [4] [5] . A serogroup A polysaccharide conjugate vaccine (MenAfriVac) has been developed for preventive mass immunization in the African meningitis belt [6] . The vaccine is highly effective at prevention of serogroup A invasive disease and carriage [7] [8] [9] , but group W and X strains remain a persistent problem. This underlines the need for an affordable vaccine that provides protection against the main serogroups causing meningitis in Africa and potentially against serogroups that may emerge in the region in the future.
GMMA generated from strains engineered to over-express immunogenic antigens that are present across all serogroups, constitute an attractive approach to vaccination. The term GMMA (Generalised Modules for Membrane Antigens) provides a clear distinction from conventional detergent-extracted outer membrane vesicles (dOMV), and native outer membrane vesicle (NOMV), which are released spontaneously from Gram-negative bacteria. GMMA differ in two crucial aspects from NOMV. First, to induce GMMA formation, the membrane structure has been modified by the deletion of genes encoding key structural components, including gna33 (meningococcus) and tolR (Shigella and Salmonella [10] ). Second, as a consequence of the genetic modification, large quantities of outer membrane bud off (the Italian word for bud is 'gemma') to provide a practical source of membrane material for vaccine production, leading to potential cost reduction. While NOMV have been used for immunogenicity studies, the yields are too low for practical vaccines.
The most promising candidate protein vaccine antigen discovered for meningococcus is factor H binding protein fHbp. The extraction process required to make dOMV removes lipoproteins, including fHbp, and increases the cost of production of dOMV relative to GMMA. The fHbp gene is present in most invasive meningococcal isolates independent of the serogroup. fHbp can be divided into three antigenic variants (v. 1, 2 or 3) [11] or into at least nine modular groups based on the combination of five variable ␣ and ␤ fHbp segments [12, 13] . Individual peptides within each variant are identified by a unique peptide ID. The outer membrane protein, PorA, is highly immunogenic but antibodies tend to provide subtype-specific protection [14] . African meningococcal isolates are relatively conserved in relation to fHbp variant and PorA subtype [15, 16] . Invasive serogroup A and X strains predominantly express fHbp v.1. PorA subtype P1.5,2 is shared by most serogroup W strains and P1.20,9 is expressed by the majority of A strains [15] . This epidemiological pattern makes a protein-based vaccine both a possible and attractive approach for sub-Saharan Africa.
A vaccine for the meningitis belt needs to be affordable and large-scale low-cost production of a GMMA vaccine has to be feasible. Deletions of gna33 or rmpM, that augment the release of these outer membrane particles can reduce costs [17] [18] [19] [20] [21] . In this study, we selected a vaccine strain based on a panel of African W strain capsule and gna33 double knock-out mutants. The isolate with the highest GMMA production was then further engineered for the deletion of lpxL1 and over-expression of fHbp v.1 (ID1). This genetic approach may form the basis for a broadly-protective, safe and economic vaccine for sub-Saharan Africa.
Materials and methods

N. meningitidis strains
Three African serogroup W, seven A and seven X strains were the target strains for serum bactericidal assays. Nine African serogroup W strains were screened as potential vaccine production strains (Table 1) . Carrier strain 1630 (ST-11) expressing PorA subvariant P1.5,2 and fHbp v.2 (ID23) was chosen for GMMA production [22] . To abolish capsule production, a fragment of the bacterial chromosome containing synX, ctrA and the promoter controlling their expression, was replaced with a spectinomycinresistance gene. First, the recombination sites were amplified with primers ctrAf Xma:CCCCCCGGGCAGGAAAGCGCTGCATAG and ctrAr XbaCGTCTAGAGGTTCAACGGCAAATGTGC; Synf KpnCGG-GGTACCCGTGGAATGTTTCTGCTCAA and Synr SpeGGACTAGTCCA-TTAGGCCTAAATGCCTG from genomic DNA from strain 1630. The fragments were inserted into plasmid pComPtac [23] upstream and downstream of the chloramphenicol resistance gene.
Subsequently the chloramphenicol resistance gene was replaced with a spectinomycin resistance cassette. The lpxL1 gene was deleted by replacement with a kanamycin resistance gene [24] , and the gna33 gene with an erythromycin resistance cassette [25] . fHbp expression was up-regulated using multicopy plasmid encoding fHbp v.1 (ID1) [26] .
GMMA preparation
Bacteria were grown at 37 • C, 5% CO 2 in 50 mL of a modified version of a meningococcus defined medium described previously [27] at 180 rpm until early stationary phase. Cells were harvested (2200 g, 30 min, 4 • C) and the culture supernatant containing the GMMA was filtered through a 0.22 m pore-size membrane (Millipore, Billerica, MA, USA). To collect GMMA, the supernatant was ultracentrifuged (142,000 × g, 2 h, 4 • C). The membrane pellet was washed with phosphate buffered saline (PBS), resuspended in PBS and sterile filtered. GMMA concentration was measured according to protein content by Lowry assay (Sigma-Aldrich, St. Louis, MO, USA). For protein and lipooligosaccharide analysis, GMMA were separated by SDS-PAGE using a 12% gel and MOPS or MES buffer (Invitrogen, Carlsbad, CA, USA). Total proteins were stained with Coomassie Blue stain. The amount of PorA was determined by densitometric quantification of the PorA protein in relation to total measurable protein. Lipooligosaccharide was visualized by treatment of the gel with periodic acid and staining with silver nitrate. The gel was developed with a solution containing 50 mg/L citric acid and 0.05% formaldehyde. fHbp was detected by Western blot using a polyclonal antibody raised in mice against recombinant fHbp ID1.
2.3. IL-6 release by human peripheral blood mononuclear cells (PBMC) stimulated with GMMA PBMC were separated from whole blood using Ficoll-Paque Plus density gradient (Amersham Pharmacia Biotec), washed with PBS and resuspended in 10% heat-inactivated fetal bovine serum (FBS)/10% Dimethyl sulfoxide and stored in liquid nitrogen until use. For stimulation, PBMCs were thawed, washed with PBS/2.5 mM EDTA and 20 g/mL DNAse (Sigma-Aldrich, St. Louis, MO, USA) and resuspended in RPMI-1640 complete (with 25 mM HEPES, glutamine, 10% FBS + 1% Antibiotics Pen-Strep). 2 × 10 5 cells/well were stimulated with GMMA (1-10 −6 g/mL final concentration) for 4 h at 37 • C. Cells were removed by centrifugation and IL-6 in the supernatants was measured by ELISA using 0.1 g of an anti-human IL-6 antibody (eBioscience, San Diego, CA, USA). A Biotin-labelled antihuman IL-6 antibody was used for detection (e-Bioscience).
Measurement of TLR-4 stimulation by NF-ÄB luciferase reporter assay
Human Embryonic Kidney 293 (HEK293) cells expressing luciferase under control of the NF-B promoter and stably transfected with human Toll-like receptor (TLR) 4, MD2 and CD14 were used. 25,000 cells/well were added to microclear luciferase plates (PBI International) and incubated for 24 h at 37 • C. GMMA (1-1.28 × 10 −5 g/mL final concentration) were added and incubated for 5 h. Cells were separated from the supernatant and lysed with passive lysis buffer (Promega, Madison, WI, USA). Luciferase assay reagent (Promega) was added and fluorescence was detected using a luminometer LMaxII 384 (Molecular Devices).
Mouse immunization
Female CD-1 mice were obtained from Charles River Laboratories (Wilmington, MA, USA). Eight mice per group were immunised Table 1 Characteristics of African N. meningitidis wild type strains used for screening of GMMA production strains and in serum bactericidal assays. intraperitoneally three times with 2 weeks intervals. Serum samples were obtained 2 weeks after the third dose. GMMA from the serogroup W Triple KO (lpxL1, capsule, gna33 KO), OE fHbp strain were given at 0.2, 1 and 5 g doses based on total protein. Two other groups of mice received 5 g of GMMA from the Double KO (lpxL1, gna33 KO) OE fHbp mutant or 5 g GMMA from the Triple KO mutant strain. Control mice were immunised with 5 g recombinant fHbp ID1 or aluminium hydroxide only. All vaccines were adsorbed on 3 mg/mL Aluminium hydroxide in a 100 L formulation containing 10 mM Histidine and 0.9 mg/mL NaCl. Sera were stored at −80 • C until use. All animal work was approved by the Italian Animal Ethics Committee (AEC project number 14112011).
Serological analysis
Anti-fHbp IgG antibody titres were measured by ELISA as previously described [28] . The coating antigen was 1 g/mL nonlipidated recombinant hexa-Histidine-tagged fHbp ID1 [11] . Serial five-fold dilutions of the serum samples starting at 1:100 were analysed. Secondary antibody was a 1:2000 dilution of alkaline phosphatase-conjugated goat-anti mouse IgG (Invitrogen, cat, no 62-6522, Lot 437983A). The titre was defined as the extrapolated dilution resulting in absorption of 1 at 405 nm after 30 min of incubation with 1 mg/mL 4-nitrophenyl phosphate disodium salt hexahydrate (Sigma-Aldrich) diluted in 1 M diethanolamine and 0.5 mM MgCl 2 , pH 9.8.
Serum bactericidal antibody (SBA) activities were measured as described before [28] . Bacteria were incubated at 37 • C, 5% CO 2 in Mueller-Hinton broth containing 0.25% glucose and 0.02 mM Cytidine-5 -monophospho-N-acetylneuraminic acid sodium salt (Sigma-Aldrich). The cells were washed with Dulbecco's PBS buffer (Sigma-Aldrich) containing 1% BSA. Each reaction mixture contained approximately 400 colony-forming units, 20% human complement screened for lack of bactericidal activity against the target strain and serial dilutions of the serum samples starting at 1:10. Bactericidal titres were defined as the reciprocal extrapolated dilution resulting in 50% killing of bacteria after 60 min incubation at 37 • C compared to the mean number of bacteria in five control reactions at time 0.
Statistical analysis
For statistical analysis, antibody titres were log 10 transformed. ELISA titres <100 were assigned the value 50, SBA titres <10 were assigned the value 5. Mann-Whitney U test was used to compare pairs of values. A probability value of <0.05 was considered statistically significant. The analysis was performed with the Graph Pad Prism software 5.01.
Results
Selection of the serogroup W GMMA production strain and generation of mutants
Nine group W strains (six carrier and three case isolates) with PorA subtype P1.5,2, collected in Ghana between 2003 and 2007, were screened as candidate GMMA production strains. To identify the isolate with highest GMMA production, gna33 was deleted from all strains. In some isolates, simultaneous deletion of the capsule decreased the GMMA release compared to the gna33 single knock-out (KO). Therefore, we generated gna33 and capsule double KO mutants of the nine W strains and compared GMMA production. These double-mutant strains released two to five-fold higher amounts of GMMA than a representative group W wild type strain (Fig. 1A) . Strain 1630 (gna33 KO, capsule KO), which released the highest quantity of GMMA, was selected for further genetic manipulation.
To generate the final vaccine strain, we deleted lpxL1 and engineered the mutant to over-express fHbp v.1, designated 'Triple KO, OE fHbp'. We also prepared two isogenic group W control strains: one with deleted lpxL1 and gna33, over-expressed fHbp v.1 with the capsule still expressed ('Double KO, OE fHbp'), and another with deleted lpxL1, capsule and gna33, but no fHbp overexpression ('Triple KO') ( Table 2 ). SDS-PAGE and Coomassie Blue staining of the proteins revealed a similar protein pattern in the three GMMA preparations. Densitometry indicated that in all three GMMA preparations, the relative amount of PorA to total protein is 5%. By silver stain, the GMMA contained similar levels of lipooligosaccharide. By capture ELISA, with recombinant fHbp as standard, approximately 3% of the total protein in GMMA from the Triple KO, OE fHbp was fHbp, and by Western blot, the two GMMA over-expressing fHbp had similar fHbp levels.
IL-6 release by human PBMC and TLR-4 activation in HEK293 cells after stimulation with GMMA
To assess the endotoxic activity of the GMMA, we measured the release of IL-6 by human PBMC after stimulation with different concentrations of GMMA from the Triple KO, OE fHbp mutant and the parent serogroup W wild type strain (Fig. 1C) . Approximately 50-fold higher concentrations of GMMA from the mutant strain were required to stimulate the release of 200 pg/mL IL-6, confirming the decrease in endotoxic activity. We measured the ability of the GMMA to stimulate human TLR-4 in transfected HEK293 cells (Fig. 1D) . Low concentrations of GMMA from the wild type bacteria stimulated TLR-4, as measured by increased NF-B expression. Approximately 1000-fold higher concentrations of GMMA from the Triple KO, OE fHbp mutant were required for equivalent TLR-4 stimulation. These results are consistent with a strongly decreased ability of the LOS in GMMA from the serogroup W mutant to lipooligosaccharide in 0.5 g GMMA. Lower panel: detection of fHbp in GMMA by Western blot using a polyclonal anti-fHbp v.1 antibody. M = molecular weight marker. Lane 1, GMMA Triple KO, OE fHbp; lane 2, GMMA Double KO, OE fHbp; lane 3, GMMA Triple KO. C. IL-6 release by human PBMCs stimulated with different concentrations of GMMA with deleted capsule, gna33 and lpxL1 and over-expressed fHbp v.1 for four hours. IL-6 release into culture supernatants was analysed by ELISA. D. Stimulation of TLR-4 in HEK293 cells transfected with human Toll-like receptor (TLR) 4, MD2 and CD14 and luciferase expressed under control of the NF-B promoter. Cells were stimulated with GMMA for five hours, lysed and emitted light was quantitated with a luminometer. The readings were divided by the control cells stimulated with PBS. Mean results and standard deviations from two independent experiments were plotted. Black circles = GMMA from the group W wild type strain 1630 used to construct the mutants. White triangles = Triple KO, OE fHbp: GMMA from the group W mutant strain with deleted capsule, lpxL1 and gna33 and over-expressed fHbp ID1. activate TLR-4 compared with GMMA from the non-detoxified parent wild type strain.
Antibody responses elicited in mice immunised with GMMA
We measured anti-fHbp v.1 antibody responses in individual serum samples by ELISA. GMMA from all mutants with overexpressed fHbp elicited high anti-fHbp antibody responses, even at the lowest dose of 0.2 g (Fig. 2) . 5 g Triple KO, OE fHbp GMMA induced significantly higher geometric mean titres than 5 g Double KO, OE fHbp GMMA (P = 0.03) or 5 g of recombinant fHbp v.1 (P < 0.001). GMMA from the Triple KO mutant without fHbp overexpression induced no measurable anti-fHbp antibody responses.
SBA responses of mice immunised with GMMA from recombinant serogroup W strains
The three serogroup W test strains were isolated in Ghana, Mali and Burkina Faso and expressed PorA subtype P1.5,2, which is identical to that expressed by the GMMA vaccine strains. Strain BF2/11 expressed fHbp v.1 (ID9) and the two other strains expressed fHbp v.2 (ID23). The seven group A strains tested were collected in Ghana, Burkina Faso, Sudan and Mali. They expressed a heterologous PorA compared to that in the GMMA, and fHbp v.1 (ID5). fHbp expression in these test strains ranged from 33 to 80% of that of a reference group B strain H44/76 with relatively high fHbp expression [11] . The seven group X strains were isolated in Burkina Faso, Ghana and Uganda. Two strains from Burkina Faso expressed fHbp ID73, the other isolates expressed ID74. The strains from Burkina Faso were sequence type 751 and 181, respectively. The two strains from Uganda were ST5403 and expressed PorA subtype P1.19,26, while the other five group X strains were P1.5-1,10-1. The two strains from Uganda differed from each other by the level of fHbp 4) . The bars show reciprocal geometric mean titres (±95% confidence interval) from four serum samples per GMMA vaccine group, containing sera from two mice each. For the strains labelled with an asterisk and the negative control group (Alum) two serum pools were analysed containing sera from four mice each and error bars indicate the standard error of the mean. GMMA vaccines: Triple KO, OE fHbp: capsule, lpxL1 and gna33 KO with over-expressed fHbp ID1, hatched bars. Triple KO: capsule, lpxL1 and gna33 KO without over-expressed fHbp, grey bars. rHis-fHbp: recombinant hexa-Histidine tagged fHbp ID1, white bars; Alum: aluminium hydroxide, black bars. Dotted lines indicate the lowest serum dilution tested (1:10).
expression. Strain Ug11/07 had 4% and Ug9/06 has 200% of the fHbp expression level compared to the reference strain (Table 1) .
GMMA with or without fHbp over-expression elicited high bactericidal titres that were not significantly different from each other against the three W strains expressing either fHbp v.1 or v.2 (Fig. 3A) . This is consistent with previous observations that bactericidal activity against strains sharing the same PorA as the GMMA-production strain is predominantly mediated by anti-PorA antibodies [26] .
GMMA from the Triple KO, OE fHbp strain induced antibodies that were able to kill six out of seven serogroup A strains (geometric mean titres [GMT] ranging from 20 to 2500) (Fig. 3B) . The only isolate that was resistant to killing was readily killed by a mouse serum raised against group A polysaccharide conjugate vaccine. The antibodies induced by the GMMA from the Triple KO, OE fHbp strain were able to kill all serogroup X strains tested (GMT = 18-5500) (Fig. 3C) . GMMA produced from the W strain which lacked fHbp v.1 over-expression (Triple KO), induced antibodies that were only able to kill one X strain (BF7/07), consistent with the majority of bactericidal antibodies induced by the GMMA vaccine being directed against fHbp. Antibodies made against the recombinant fHbp ID1 were only bactericidal against serogroup X strain Ug9/06 with the highest fHbp expression.
We investigated the dose-dependent bactericidal antibody response against one W (1630), A (N2602) and X (BF7/07) isolate (Fig. 4A) . Sera raised against GMMA with over-expressed fHbp were bactericidal against these strains in a dose-dependent manner (Spearman Rank P = 0.001 for group A and P < 0.0001 for group W and X) with killing occurring at all three doses (0.2, 1 and 5 g). GMMA from the triple KO, OE fHbp mutant was prepared from a mutant with deleted capsule expression in order to attenuate virulence of the vaccine strain and reduce serogroup-specific antibody production. To test the latter, we investigated whether maintaining capsule expression in the GMMA-producing strain affects the bactericidal antibody response. Sera from mice immunised with GMMA prepared from the Triple KO, OE fHbp vaccine strain had significantly higher SBA activity against three of five A and X strains tested than GMMA from the isogenic mutant that expressed the capsule (Fig. 4B) . These data are consistent with the hypothesis that deletion of capsule biosynthesis in the GMMA-production strain not only decreases virulence, but also increases antibody responses towards non-capsular antigens, such as fHbp.
Discussion
The group A polysaccharide conjugate vaccine, MenAfriVac, is highly effective at prevention of serogroup A invasive disease and carriage [7] [8] [9] . However, other serogroups, in particular W and more recently X, are increasingly contributing to the burden of meningococcal disease in sub-Saharan Africa [3, [29] [30] [31] [32] . Additionally, other meningococcal serogroups, e.g. group C, that, although not having caused outbreaks in recent years, may become a threat in the future. The challenge for future vaccine approaches for the meningitis belt is to develop a meningococcal vaccine that is not only affordable, but provides broad cross-serogroup protection against meningococcus, and complements the roll out pneumococcal vaccination to deal with the problem of pneumococcal meningitis in the region.
GMMA from recombinant meningococcal strains offer a promising option. They contain protein antigens (e.g. fHbp) which induce antibodies with serogroup independent cross protection. In addition, a simple, economic and scalable procedure for their preparation has been developed with minimal downstream processing required, which enables large quantities of GMMA vaccine to be produced at low cost [10] . While strains containing deletions of lpxL1 and capsule synthesis genes with up-regulated fHbp expression have been described [33, 34] , our approach incorporates the additional deletion of gna33 in order to enhance the level of GMMA production, and consequently the potential affordability of the vaccine for use in Africa. The mechanism of up-regulation of GMMA production is not fully understood. Our findings indicate that GMMA release by different gna33 KO strains is variable, indicating a requirement to screen multiple strains for high level GMMA release.
We tested bactericidal activity of sera from immunised mice against 17 group A, W and X strains. Five g of the GMMA from the Triple KO, OE fHbp group W strain induced SBA responses against 16 (94%) of these isolates. Ability to kill the A and X strains was attributable to fHbp which comprises only about 3% of the total GMMA protein. In comparison, 5 g recombinant fHbp ID1 induced a detectable bactericidal antibody response only against one X strain which had the highest level of fHbp expression. This is consistent with previous studies with NOMV demonstrating that fHbp expressed in the native membrane environment induces antibodies with greater functional activity than vaccines containing recombinant fHbp [15, 35, 36] .
Previous studies have demonstrated broad cross-protection of NOMV vaccines against a panel of diverse African strains [15, 34, 37] . We did not compare our GMMA vaccine directly with NOMV. Nevertheless, the strong bactericidal activity of the GMMA-induced antibodies against strains with homologous or heterologous PorA and different fHbp ID types (ID 5, 73 and 74), suggests that the new combination of mutations, including deletion of gna33, that all affect the outer surface, does not impair the immunogenicity of the main antigens, fHbp and PorA. It has been shown that decreased SBA titres are induced when mice expressing human factor H are immunised with NOMV over-expressing wild type fHbp [38] . This can be overcome by introducing the R41S mutation into the fHbp gene of the vaccine-producing strain [38, 39] . The aim of the current study was to serve as a first proof of concept in mice for a GMMA meningococcal candidate vaccine and the R41S mutation was not incorporated into our vaccine design. We are currently investigating the utility of this mutation in GMMA vaccines.
For safety and immunological reasons, we engineered the vaccine strain to have deleted lpxL1 and be non-encapsulated which is associated with the inability to cause invasive disease [40] . As described for group B strains, deletion of lpxL1 resulted in decreased ability of the group W GMMA to stimulate Il-6 release by human PBMC and activate TLR-4. These data indicate that genetic detoxification of meningococcal LOS by inactivation of lpxL1 is a common mechanism among different serogroups.
Consistent with our hypothesis that removal of the capsule would enhance the level of bactericidal activity induced against non-W serogroups, GMMA produced by the non-encapsulated mutant W strain induced higher bactericidal titres against A and X strains, than the isogenic encapsulated control. The underlying mechanisms require further investigation. Capsular polysaccharide on GMMA may mask fHbp epitopes from the immune system, particularly from fHbp-specific B cells. An alternative explanation is that capsular polysaccharide on GMMA may serve as an antigenic competitor, interfering and decreasing the immune response to common protein antigens such as fHbp, although addition of external group A polysaccharide conjugate did not impair antibody responses to protein antigens in a meningococcal NOMV vaccine [34] . Thermostability is also highly desirable for any new vaccine targeted at the African meningitis belt and we are currently investigating this quality in our GMMA vaccine.
In conclusion, the findings of this study provide support for a GMMA-based vaccine approach as an affordable and broadlyprotective vaccine strategy against meningococcal meningitis for Africa.
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